Anaptysbio (ANAB) Other financing activities (2016 - 2021)
Anaptysbio's (ANAB) quarterly Other financing activities came in at $241000.0 in Q3 2021, down 8.37% YoY from $263000.0 in Q3 2020, and down 56.5% on a QoQ basis from $554000.0 in Q2 2021.
Anaptysbio (ANAB) Other financing activities (2016 - 2021) Analysis & Trends
Anaptysbio (ANAB) has 6 years of Other financing activities data on file, last reported at $241000.0 in Q3 2021.
- Quarterly Other financing activities fell 8.37% year-over-year to $241000.0 in Q3 2021, while the trailing twelve-month figure through Sep 2021 was $1.1 million (up 224.63% YoY) and the FY2020 annual result came in at $496000.0, changed N/A from the prior year.
- Other financing activities eased to $241000.0 in Q3 2021, from $554000.0 in the prior quarter.
- In the past five years, Other financing activities ranged from a high of $1.4 million in Q2 2018 to a low of -$2.1 million in Q4 2018.
- A 5-year average of $108947.4 and a median of $215000.0 in 2019 frame the typical range for Other financing activities.
- The widest YoY moves for Other financing activities: up 3844.44% in 2017, down 1637.5% in 2017.
- Tracing ANAB's Other financing activities over 5 years: stood at -$278000.0 in 2017, then slumped by 641.73% to -$2.1 million in 2018, then jumped by 39.72% to -$1.2 million in 2019, then soared by 110.14% to $126000.0 in 2020, then surged by 91.27% to $241000.0 in 2021.
- The last three Other financing activities figures came in at $241000.0 (Q3 2021), $554000.0 (Q2 2021), and $167000.0 (Q1 2021), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Anaptysbio | 1.70 Bn | 1.41 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2021 | 241,000.00 |
| Sep 30, 2021 | 241,000.00 |
| Jun 30, 2021 | 554,000.00 |
| Jun 30, 2021 | 554,000.00 |
| Mar 31, 2021 | 167,000.00 |
| Mar 31, 2021 | 167,000.00 |
| Dec 31, 2020 | 126,000.00 |
| Dec 31, 2020 | 126,000.00 |
| Sep 30, 2020 | 263,000.00 |
| Sep 30, 2020 | 263,000.00 |
| Jun 30, 2020 | 71,000.00 |
| Jun 30, 2020 | 71,000.00 |
| Mar 31, 2020 | 36,000.00 |
| Mar 31, 2020 | 36,000.00 |
| Dec 31, 2019 | -1.24 Mn |
| Dec 31, 2019 | -1.24 Mn |
| Sep 30, 2019 | 454,000.00 |
| Sep 30, 2019 | 454,000.00 |
| Jun 30, 2019 | 215,000.00 |
| Jun 30, 2019 | 215,000.00 |